---
title: 'Durvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary
  Tract Cancer: An Exploratory Analysis of Real-World Data'
date: '2024-02-28'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38416377/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240228170637&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: The treatment of advanced patients with BTC with durvalumab
  and gem/cis, even beyond the inclusion criteria of the TOPAZ-1 trial, shows promising
  ...'
disable_comments: true
---
CONCLUSIONS: The treatment of advanced patients with BTC with durvalumab and gem/cis, even beyond the inclusion criteria of the TOPAZ-1 trial, shows promising ...